Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
Janssen-Cilag Pty Ltd
This trial consists of a screening phase, treatment phase and post-treatment phase. The total duration of the trial will be up to 2.7 years. Efficacy assessments will include radiographic image assessments, positron emission tomography scan, bone marrow assessment, endoscopy or colonoscopy, physical examinations. Safety will be monitored throughout the trial. The treatment phase will be split into two parts. Part A: Dose Escalation and Part B: Dose Expansion. In Part A, eligible patients will receive intravenous or subcutaneous JNJ-75348780 weekly, with doses escalated sequentially until a recommended dose is identified. Patients enrolled in Part B will receive JNJ-75348780 at the recommended dose.